Praful Ravi

Jan 7, 2025 | nature.com | Praful Ravi |Daniel E. Spratt

AbstractPatients treated with RT and long-term androgen deprivation therapy (ltADT) for high-risk localized prostate cancer (HRLPC) with 1 high-risk factor (any of Gleason ≥8, PSA > 20 ng/mL, ≥cT3; “high-risk”) have better outcomes than those with 2–3 factors and/or cN1 disease (“very high risk”). We evaluated whether this risk stratification could determine benefit from ltADT versus short-term (stADT).

Aug 21, 2024 | onclive.com | Praful Ravi

CommentaryVideoAugust 21, 2024Author(s):Praful K. Ravi, MB, BChir, MRCP, discusses the prognostic impact of residual cancer burden on long-term outcomes in high-risk localized prostate cancer. Praful K.

Aug 14, 2024 | onclive.com | Praful Ravi

Praful K. Ravi, MB, BChir, MRCP, medical oncologist, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, instructor, medicine, Harvard Medical School, discusses findings from a pooled analysis of 5 phase 2 trials conducted between 2006 to 2018 that evaluated the use of neoadjuvant androgen receptor pathway inhibitors (ARPIs) prior to radical prostatectomy in patients with high-risk, localized prostate cancer.

Jul 29, 2024 | onclive.com | Praful Ravi

Praful K. Ravi, MB, BChir, MRCP, medical oncologist, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, instructor, medicine, Harvard Medical School, discusses the prognostic value and potential use of residual cancer burden (RCB) to guide intensified neoadjuvant treatment strategies for patients with high-risk localized prostate cancer.

May 21, 2024 | europeanurology.com | Praful Ravi |Wanling Xie |Marc E. Buyse |Susan Halabi |Philip W. Kantoff |Oliver Sartor